FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More


Laura Jones reports on an FDA approval in chronic lymphocytic leukemia, a recommendation for an agent in second-line non–small cell lung cancer, an approval sought in pediatric acute lymphoblastic leukemia, and a missed endpoint in a phase III study for glioblastoma multiforme.


Leave A Reply

Your email address will not be published.